AAAAAA
Results: 1-25/58
Authors:
Jordan, VC
Gapstur, S
Morrow, M
Citation: Vc. Jordan et al., Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease, J NAT CANC, 93(19), 2001, pp. 1449-1457
Authors:
Jordan, VC
Citation: Vc. Jordan, Estrogen, selective estrogen receptor modulation, and coronary heart disease: Something or nothing, J NAT CANC, 93(1), 2001, pp. 2-4
Authors:
Schafer, JM
Lee, ES
Dardes, RC
Bentrem, D
O'Regan, RM
Reyes, AD
Jordan, VC
Citation: Jm. Schafer et al., Analysis of cross-resistance of the selective estrogen receptor modulatorsarzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts, CLIN CANC R, 7(8), 2001, pp. 2505-2512
Authors:
Chisamore, MJ
Ahmed, Y
Bentrem, DJ
Jordan, VC
Tonetti, DA
Citation: Mj. Chisamore et al., Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase C alpha, CLIN CANC R, 7(10), 2001, pp. 3156-3165
Authors:
Jordan, VC
Citation: Vc. Jordan, Oestrogen receptors, growth factors and the control of breast cancer, BREAST, 10, 2001, pp. 27-35
Authors:
Levenson, AS
Schafer, JIM
Bentrem, DJ
Pease, KM
Jordan, VC
Citation: As. Levenson et al., Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351, J STEROID B, 76(1-5), 2001, pp. 61-70
Authors:
Takei, H
Iino, Y
Horiguchi, J
Maemura, M
Koibuchi, Y
Yokoe, T
Morishita, Y
Jordan, VC
Citation: H. Takei et al., Tamoxifen-failed male breast cancer with a high level of circulating estrogen: Report of a case, SURG TODAY, 31(2), 2001, pp. 149-151
Authors:
Cauley, JA
Norton, L
Lippman, ME
Eckert, S
Krueger, KA
Purdie, DW
Farrerons, J
Karasik, A
Mellstrom, D
Ng, KW
Stepan, JJ
Powles, TJ
Morrow, M
Costa, A
Silfen, SL
Walls, EL
Schmitt, H
Muchmore, DB
Jordan, VC
Citation: Ja. Cauley et al., Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial, BREAST CANC, 65(2), 2001, pp. 125-134
Authors:
O'Regan, RM
Jordan, VC
Citation: Rm. O'Regan et Vc. Jordan, Tamoxifen to raloxifene and beyond, SEMIN ONCOL, 28(3), 2001, pp. 260-273
Authors:
Fournier, DB
Chisamore, M
Lurain, JR
Rademaker, AW
Jordan, VC
Tonetti, DA
Citation: Db. Fournier et al., Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: Possible role in AP-1-mediated proliferation of ER-negative endometrial cancer, GYNECOL ONC, 81(3), 2001, pp. 366-372
Authors:
Bentrem, DJ
Dardes, RC
Liu, H
Maccgregor-Schafer, J
Zapf, JW
Jordan, VC
Citation: Dj. Bentrem et al., Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen, ENDOCRINOL, 142(2), 2001, pp. 838-846
Authors:
Liu, H
Lee, ES
De Los Reyes, A
Zapf, JW
Jordan, VC
Citation: H. Liu et al., Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex, CANCER RES, 61(9), 2001, pp. 3632-3639
Authors:
Jordan, VC
Schafer, JM
Levenson, AS
Liu, H
Pease, KM
Simons, LA
Zapf, JW
Citation: Vc. Jordan et al., Molecular classification of estrogens, CANCER RES, 61(18), 2001, pp. 6619-6623
Authors:
Jordan, VC
Citation: Vc. Jordan, Selective estrogen receptor modulation: A personal perspective, CANCER RES, 61(15), 2001, pp. 5683-5687
Authors:
O'Regan, RM
Jordan, VC
Citation: Rm. O'Regan et Vc. Jordan, Chemoprevention of breast cancer, CANC TREAT, 2001, pp. 137-154
Authors:
Jordan, VC
Citation: Vc. Jordan, How is tamoxifen's action subverted?, J NAT CANC, 92(2), 2000, pp. 92-94
Authors:
Yao, K
Lee, ES
Bentrem, DJ
England, G
Schafer, JIM
O'Regan, RM
Jordan, VC
Citation: K. Yao et al., Antitumor action of physiological estradiol on tamoxifen-stimulated breasttumors grown in athymic mice, CLIN CANC R, 6(5), 2000, pp. 2028-2036
Authors:
Lee, ES
Schafer, JM
Yao, K
England, G
O'Regan, RM
De Los Reyes, A
Jordan, VC
Citation: Es. Lee et al., Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice, CLIN CANC R, 6(12), 2000, pp. 4893-4899
Authors:
Schafer, JM
Lee, ES
O'Regan, RM
Yao, K
Jordan, VC
Citation: Jm. Schafer et al., Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice, CLIN CANC R, 6(11), 2000, pp. 4373-4380
Authors:
Jordan, VC
Citation: Vc. Jordan, Antiestrogens: Clinical applications of pharmacology, J SOC GYN I, 7(1), 2000, pp. S47-S48
Authors:
Morrow, M
Jordan, VC
Citation: M. Morrow et Vc. Jordan, Tamoxifen for the prevention of breast cancer in the high-risk woman, ANN SURG O, 7(1), 2000, pp. 67-71
Authors:
Dardes, RDM
Horiguchi, J
Jordan, VC
Citation: Rdm. Dardes et al., A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labelling index in women with primary breast cancer, INT J ONCOL, 16(1), 2000, pp. 25-30
Authors:
Jordan, VC
Citation: Vc. Jordan, Progress in the prevention of breast cancer: concept to reality, J STEROID B, 74(5), 2000, pp. 269-277
Authors:
Hozumi, Y
Kawano, M
Jordan, VC
Citation: Y. Hozumi et al., In vitro study of the effect of raloxifene on lipid metabolism compared with tamoxifen, EUR J ENDOC, 143(3), 2000, pp. 427-430
Authors:
Takei, H
Lee, ES
Cisneros, A
Jordan, VC
Citation: H. Takei et al., Effects of angiogenesis inhibitor TNP-470 on tamoxifen-stimulated MCF-7 breast tumors in nude mice, CANCER LETT, 155(2), 2000, pp. 129-135